US Patent 8,829,013: Ruxolitinib Phosphate Claims, Scope, Expiration, and Generic-Entry Risk
US Patent 8,829,013 protects methods of treating myeloproliferative disorders with the R-enantiomer of ruxolitinib as its phosphoric acid salt, commonly identified as ruxolitinib phosphate. The claims cover polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, now generally called primary or secondary myelofibrosis. The patent also reaches crystalline 1:1 ruxolitinib phosphate, oral pharmaceutical compositions, and tablets.
The patent is a method-of-use patent, not a broad chemical-composition patent. Its commercial relevance is tied to Jakafi tablets and the use of ruxolitinib phosphate in myelofibrosis and polycythemia vera. The core patent family is generally associated with an expiration date of December 20, 2027, subject to any applicable patent-term adjustment or pediatric extension. [1][2][3]
What drug does US Patent 8,829,013 protect?
The claimed active ingredient is the R-enantiomer of a selective Janus kinase inhibitor:
| Claim element |
Chemical or commercial identity |
| Active compound |
Ruxolitinib |
| Salt form |
Ruxolitinib phosphate |
| Stereochemistry |
R configuration |
| Salt ratio in dependent claims |
1:1 ruxolitinib-to-phosphoric-acid salt |
| Drug product |
Jakafi tablets in the United States |
| Primary targets |
JAK1 and JAK2 |
| Main claimed diseases |
Myelofibrosis, polycythemia vera, and essential thrombocythemia |
Ruxolitinib is marketed by Incyte Corporation in the United States under the brand name Jakafi. The FDA approved Jakafi in 2011 for intermediate- or high-risk myelofibrosis and expanded the label in 2014 to include adults with polycythemia vera who had an inadequate response to or were intolerant of hydroxyurea. [4]
The patent claims use the older term “myeloid metaplasia with myelofibrosis,” or MMM. In current clinical and regulatory usage, this disease is generally described as myelofibrosis.
What are the independent claims in US Patent 8,829,013?
Claims 1 and 7 are the two independent claims.
Claim 1: administration of ruxolitinib phosphate
Claim 1 requires:
- A patient with a myeloproliferative disorder;
- Administration of a therapeutically effective amount;
- The specific R-enantiomer of ruxolitinib;
- The phosphoric acid salt of that compound.
Claims 2 through 4 narrow claim 1 to:
- Polycythemia vera;
- Essential thrombocythemia; or
- Myeloid metaplasia with myelofibrosis.
Claims 5 and 6 add crystalline and stoichiometric limitations. Claim 5 requires a crystalline salt, while claim 6 specifies the 1:1 ruxolitinib-phosphoric-acid salt.
Claim 7: pharmaceutical composition administration
Claim 7 covers administering a pharmaceutical composition containing:
- Ruxolitinib phosphate; and
- A pharmaceutically acceptable carrier.
Claims 8 through 10 repeat the disease limitations in claims 2 through 4. Claims 11 and 12 add:
- Suitability for oral administration; and
- Tablet dosage form.
Claims 13 and 14 add crystalline and 1:1 salt limitations corresponding to claims 5 and 6.
How broad is the scope of the patent claims?
The claims are narrower than a general claim to ruxolitinib or to all JAK-inhibitor treatment of myeloproliferative disease.
Scope limitations that materially narrow the claims
The accused product or conduct must generally involve the following elements:
| Limitation |
Effect on claim scope |
| R-enantiomer |
Excludes the S-enantiomer and racemic material unless the accused product contains the claimed compound in an infringing form |
| Phosphoric acid salt |
Excludes unrelated salts and potentially the unprotonated free base |
| Myeloproliferative disorder |
Limits the use to the claimed disease category |
| Therapeutically effective amount |
Requires treatment-level administration rather than incidental exposure |
| Crystalline form |
Applies only to dependent claims 5, 6, 13, and 14 |
| 1:1 salt |
Applies only to claims 6 and 14 |
| Pharmaceutical carrier |
Required by claim 7 and its dependents |
| Oral tablet |
Required only by claims 11 and 12 |
Claim 1 does not require a particular dose, dosing frequency, treatment duration, patient mutation, disease-risk category, prior therapy, or response endpoint. It also does not expressly require a tablet, oral administration, or a particular crystal form.
Claim 7 is directed to treatment using a pharmaceutical composition. It is more product-specific than claim 1 because it requires a composition containing the salt and a pharmaceutically acceptable carrier. Claims 11 and 12 are commercially important because they align with the marketed oral tablet product.
What formulations are protected by US Patent 8,829,013?
The patent does not claim every ruxolitinib formulation as a standalone composition of matter. It claims treatment methods using compositions that contain ruxolitinib phosphate.
The protected formulation categories are:
| Formulation category |
Relevant claims |
Commercial significance |
| Ruxolitinib phosphate administered as a treatment |
1-6 |
Broadest method-of-treatment coverage |
| Composition with a pharmaceutically acceptable carrier |
7-10, 13-14 |
Covers drug product use |
| Oral composition |
11 |
Aligns with Jakafi tablets |
| Tablet |
12 |
Directly relevant to generic tablet products |
| Crystalline salt |
5-6, 13-14 |
Adds solid-state and salt-form limitations |
| 1:1 crystalline salt |
6 and 14 |
Narrowest expressly defined form |
The patent does not, based on the listed claims, require a particular excipient, coating, dissolution profile, particle-size distribution, release profile, or manufacturing process. A separate formulation patent would be needed to create those additional limitations.
What diseases are covered by the patent?
The patent expressly covers three disease indications.
Polycythemia vera
Polycythemia vera is a chronic myeloproliferative neoplasm characterized by abnormal production of red blood cells and, in many patients, elevated platelets or white blood cells. FDA-approved Jakafi use includes patients with polycythemia vera who have an inadequate response to or are intolerant of hydroxyurea. [4]
Essential thrombocythemia
Essential thrombocythemia is expressly recited in claims 3 and 9. It is not the primary current U.S. Jakafi indication identified in the FDA label. The claim language nevertheless creates method-of-use coverage for treatment of the disease if the other claim elements are met.
Myeloid metaplasia with myelofibrosis
This term appears in claims 4 and 10. The current clinical term is myelofibrosis. Jakafi is FDA-approved for adults with intermediate- or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. [4]
When does US Patent 8,829,013 lose exclusivity?
The expected base expiration date is December 20, 2027, based on the ruxolitinib patent family’s priority and statutory patent-term framework. The effective date may differ if the issued patent has patent-term adjustment or if FDA pediatric exclusivity applies to the relevant product and patent listing. [1][2][3]
| Exclusivity layer |
Expected timing |
| US Patent 8,829,013 base term |
December 20, 2027, subject to adjustment |
| Potential pediatric extension |
Up to six additional months if applicable |
| Small-molecule regulatory exclusivity |
Separate from patent term and indication-specific |
| ANDA launch restriction |
Controlled by listed patents, litigation, settlements, and court outcomes |
Patent expiration does not automatically produce immediate generic entry. An ANDA applicant may enter earlier through a successful Paragraph IV challenge, a court judgment of non-infringement or invalidity, a settlement date, or an authorized-generic arrangement.
What is the Orange Book status of ruxolitinib and Jakafi?
Jakafi is an FDA-approved small-molecule drug and is subject to the Hatch-Waxman ANDA pathway. The relevant listed patents have included patents directed to the ruxolitinib compound, therapeutic uses, and related product protection. The FDA Orange Book identifies patents and use codes supplied by the NDA holder; it does not decide patent validity or infringement. [2][5]
US Patent 8,829,013 is commercially important because its claimed indications overlap with Jakafi’s core hematologic uses. The scope is narrower than the complete Jakafi patent estate because it does not independently cover every use of ruxolitinib, including dermatologic use of ruxolitinib cream.
Opzelura, the ruxolitinib cream product, is approved for atopic dermatitis and nonsegmental vitiligo. Those indications are outside the express myeloproliferative-disorder limitations in US Patent 8,829,013. [6]
Which patents make up the broader ruxolitinib patent landscape?
The patent estate generally includes several layers:
| Patent category |
Representative protection |
Relevance |
| Core chemical patent |
Ruxolitinib compounds and related intermediates |
Protects the active pharmaceutical ingredient |
| Salt and solid-state patents |
Ruxolitinib phosphate and crystalline forms |
Protects commercial drug substance forms |
| Myelofibrosis method patents |
Treatment of myelofibrosis with ruxolitinib |
Supports Jakafi’s original indication |
| Polycythemia vera method patents |
Treatment of PV |
Supports the later hematology indication |
| Formulation patents |
Tablets, compositions, and manufacturing characteristics |
Can affect generic product design |
| Dermatology patents |
Topical ruxolitinib formulations and uses |
Relevant to Opzelura rather than Jakafi tablets |
US Patent 8,829,013 should therefore be analyzed as one layer of the estate, not as the complete exclusivity position. The most important practical distinction is between:
- Claims covering the molecule;
- Claims covering the phosphate salt or crystal form;
- Claims covering hematologic indications; and
- Claims covering topical formulations and dermatologic indications.
How strong is the patent estate for US Patent 8,829,013?
The patent has meaningful commercial strength for a generic seeking to market ruxolitinib phosphate tablets for myelofibrosis or polycythemia vera. Its strengths are:
- It identifies the commercial R-enantiomer and phosphate salt.
- It covers the main hematology indications for Jakafi.
- The tablet and oral-composition claims map onto the marketed product.
- The claims do not depend on a narrow dose or a specific clinical response.
- Method claims can be asserted against a generic’s proposed labeling when the label directs the patented use.
The main vulnerabilities and design-around considerations are:
- A generic may challenge the patent’s validity based on anticipation, obviousness, written description, enablement, or claim construction.
- An applicant may seek a Paragraph IV certification against the listed patent.
- A product labeled for a noncovered indication may reduce method-of-use exposure, although actual prescribing and inducement issues remain relevant.
- Claims requiring the phosphate salt may not reach a genuinely different salt or formulation unless that product contains or converts to the claimed form.
- Dependent claims requiring crystallinity or a 1:1 stoichiometry are narrower than claim 1 and may be more vulnerable to non-infringement based on solid-state characterization.
The patent’s practical strength is highest against an ANDA for the same ruxolitinib phosphate tablet labeled for myelofibrosis or polycythemia vera.
What Paragraph IV challenges and litigation affect ruxolitinib?
A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For a ruxolitinib tablet ANDA, the applicant may challenge patents covering the active ingredient, salt, formulation, or hematology indications.
The litigation analysis should distinguish between:
- Challenges to the core compound patent;
- Challenges to US Patent 8,829,013;
- Challenges to formulation or crystal-form patents;
- Settlement agreements that provide a licensed future-entry date;
- Court decisions that affect only one ANDA applicant or one patent.
A Paragraph IV filing can trigger a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation is resolved earlier or the statutory stay is otherwise terminated. [7]
The existence of a Paragraph IV certification does not establish generic launch permission. The commercial outcome depends on the asserted patents, litigation judgment, settlement terms, exclusivity held by the first filer, and any launch-at-risk decision.
What generic entry risks exist for Jakafi tablets?
The likely generic-entry scenarios are:
| Scenario |
Effect on market entry |
| Patent litigation loss for the brand |
Earlier approval or launch may occur, subject to remaining patents |
| Settlement with an agreed entry date |
Entry occurs on the contractual date |
| Successful non-infringement position |
Generic may avoid the asserted patent |
| Successful invalidity challenge |
The challenged patent may no longer block entry |
| Label carve-out |
Generic may omit a patented indication if FDA permits the labeling strategy |
| Authorized generic |
Brand-linked competition can precede or accompany independent ANDA entry |
| Full patent expiry |
Broadest pathway for unrestricted generic competition |
A label carve-out may be difficult where the patented disease indication is central to the product’s commercial use. For a hematology product, the overlap between approved labeling and patent claims is commercially significant.
How does US Patent 8,829,013 compare with biosimilar risk?
Biosimilar risk is not the relevant framework for ruxolitinib. Ruxolitinib is a chemically synthesized small molecule regulated through the ANDA pathway, not a biologic regulated through the biosimilar pathway under the Biologics Price Competition and Innovation Act.
The principal competitive threat is therefore generic ruxolitinib, including:
- Ruxolitinib phosphate tablets;
- Potential alternative salt or formulation products;
- Products using a permissible indication carve-out;
- Authorized-generic competition.
Biosimilar approval, interchangeability, and biologic reference-product exclusivity do not apply to Jakafi tablets.
What licensing and commercial issues affect the patent estate?
Incyte is the principal U.S. commercial party associated with Jakafi. Eli Lilly has been associated with certain ex-U.S. commercialization rights for ruxolitinib, including a collaboration involving myelofibrosis and polycythemia vera markets outside the United States. [8]
Licensing terms do not change the scope of US Patent 8,829,013. They can change:
- Who controls enforcement;
- Who receives royalties;
- Which party manages generic settlements;
- The allocation of launch and litigation costs;
- The economic value of an agreed generic-entry date.
For valuation purposes, exposure is concentrated in U.S. Jakafi sales for myelofibrosis and polycythemia vera. Opzelura revenues should be analyzed separately because the topical product has a different formulation, labeling profile, and patent set.
Key Takeaways
- US Patent 8,829,013 covers treatment of myeloproliferative disorders with ruxolitinib phosphate.
- The express diseases are polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
- Claims 1 and 7 are the principal independent claims.
- Claims 11 and 12 are commercially aligned with oral Jakafi tablets.
- Claims 5, 6, 13, and 14 narrow protection to crystalline, including 1:1, ruxolitinib phosphate.
- The expected base expiration is December 20, 2027, subject to patent-term adjustment and any applicable pediatric extension.
- The patent is part of a broader ruxolitinib estate that includes compound, salt, formulation, indication, and topical-product patents.
- Generic competition is governed by ANDA Paragraph IV litigation, settlements, patent expiry, and possible label carve-outs.
- Biosimilar risk does not apply because ruxolitinib is a small-molecule drug.
FAQs About US Patent 8,829,013 and Ruxolitinib
Does US Patent 8,829,013 cover ruxolitinib free base?
The listed claims specifically recite the phosphoric acid salt of the R-enantiomer. They do not present a general standalone claim to ruxolitinib free base.
Does the patent cover ruxolitinib cream?
No express claim is directed to topical treatment, atopic dermatitis, vitiligo, or a dermatologic formulation. The claims target myeloproliferative disorders and are principally relevant to oral Jakafi products.
Can a generic omit the polycythemia vera indication?
A generic may pursue an indication carve-out where permitted by FDA regulations and where the remaining label does not induce infringement of the patented use. The analysis depends on the final label and the surviving patent claims.
Is essential thrombocythemia an FDA-approved Jakafi indication?
Essential thrombocythemia is expressly included in claims 3 and 9, but it is not identified as a principal FDA-approved Jakafi indication in the current U.S. labeling cited here.
What is the most important patent for a generic Jakafi tablet?
The answer depends on the filing date and proposed label. The core compound patent, ruxolitinib phosphate and crystal-form patents, formulation patents, and method-of-use patents must be evaluated together. US Patent 8,829,013 is especially relevant to a generic seeking labeling for myelofibrosis or polycythemia vera.
References
- United States Patent and Trademark Office. (2014). US Patent No. 8,829,013, methods of treating myeloproliferative disorders.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- United States Code, 35 U.S.C. §§ 154, 156.
- U.S. Food and Drug Administration. (2023). Jakafi (ruxolitinib) prescribing information. Incyte Corporation.
- U.S. Food and Drug Administration. (2024). Approved drug product listing for Jakafi (ruxolitinib phosphate).
- U.S. Food and Drug Administration. (2024). Opzelura (ruxolitinib) cream prescribing information. Incyte Corporation.
- United States Code, 21 U.S.C. § 355(j)(5)(B)(iii).
- Eli Lilly and Company. (2016). Annual report.